Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381815 | 0.82 | ERN1 (0.42) | LMNAALDH1A1ERN1NOTUM | |
| SCHEMBL29952034 | 0.82 | ERN1 (0.42) | LMNAALDH1A1ERN1NOTUM | |
| Ortho-Phthalaldehyde SCHEMBL2474511 | 0.76 | LMNA (0.52) | LMNAALDH1A1GAAL3MBTL1ERN1 | |
| SCHEMBL2543778 | 0.70 | CYP1A2 (0.41) | LMNAALDH1A1GAAL3MBTL1ERN1 | |
| Alcohol SCHEMBL27806922 | 0.70 | MEN1 (0.43) | LMNAALDH1A1GAAL3MBTL1ERN1 | |
| SCHEMBL19715842 | 0.69 | PDCD1 (0.49) | — | |
| SCHEMBL11323911 | 0.69 | LMNA (0.40) | LMNAALDH1A1GAAL3MBTL1SMN1; SMN2 | |
| SCHEMBL6918730 | 0.69 | LMNA (0.40) | LMNAALDH1A1GAAERN1SMN1; SMN2 | |
| Salicyladehyde SCHEMBL6903346 | 0.69 | TRIM24 (0.60) | LMNAALDH1A1ERN1SMN1; SMN2 | |
| SCHEMBL3905460 | 0.69 | LMNA (0.40) | LMNAALDH1A1GAAL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114948-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-7790721-B2 | Pyrroloquinoxalinone inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2114948-A2 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | Abbott Laboratories (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008082887-A2 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161292-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | LMNA 688/4885ALDH1A1 1358/4885GAA 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.